These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 26852185)

  • 81. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Non-alcoholic Fatty Liver Disease (NAFLD)--A Review.
    Karim MF; Al-Mahtab M; Rahman S; Debnath CR
    Mymensingh Med J; 2015 Oct; 24(4):873-80. PubMed ID: 26620035
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
    Heebøll S; Kreuzfeldt M; Hamilton-Dutoit S; Kjær Poulsen M; Stødkilde-Jørgensen H; Møller HJ; Jessen N; Thorsen K; Kristina Hellberg Y; Bønløkke Pedersen S; Grønbæk H
    Scand J Gastroenterol; 2016; 51(4):456-64. PubMed ID: 26784973
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
    Jump DB; Lytle KA; Depner CM; Tripathy S
    Pharmacol Ther; 2018 Jan; 181():108-125. PubMed ID: 28723414
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Beneficial Effects of Dietary Polyphenols in the Prevention and Treatment of NAFLD: Cell-Signaling Pathways Underlying Health Effects.
    Echeverría F; Bustamante A; Sambra V; Álvarez D; Videla L; Valenzuela R
    Curr Med Chem; 2022; 29(2):299-328. PubMed ID: 34525916
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Bioactive Components and Possible Activities of Medicinal Mushrooms in Alleviating the Pathogenesis of Nonalcoholic Fatty Liver Disease (Review).
    Lo HC
    Int J Med Mushrooms; 2021; 23(3):29-41. PubMed ID: 33822497
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis.
    Atarashi M; Izawa T; Miyagi R; Ohji S; Hashimoto A; Kuwamura M; Yamate J
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29401710
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.
    Liu W; Baker SS; Baker RD; Zhu L
    Curr Drug Targets; 2015; 16(12):1301-14. PubMed ID: 25915484
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Parker HM; Johnson NA; Burdon CA; Cohn JS; O'Connor HT; George J
    J Hepatol; 2012 Apr; 56(4):944-51. PubMed ID: 22023985
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Impairment of reproductive function in a male rat model of non-alcoholic fatty liver disease and beneficial effect of N-3 fatty acid supplementation.
    Li Y; Liu L; Wang B; Xiong J; Li Q; Wang J; Chen D
    Toxicol Lett; 2013 Oct; 222(2):224-32. PubMed ID: 23747427
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents.
    Ued Fda V; Weffort VR
    Rev Paul Pediatr; 2013 Dec; 31(4):523-30. PubMed ID: 24473959
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effects of resveratrol and other polyphenols in hepatic steatosis.
    Aguirre L; Portillo MP; Hijona E; Bujanda L
    World J Gastroenterol; 2014 Jun; 20(23):7366-80. PubMed ID: 24966607
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Active vitamin D impedes the progression of non-alcoholic fatty liver disease by inhibiting cell senescence in a rat model.
    Ma M; Long Q; Chen F; Zhang T; Wang W
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):513-523. PubMed ID: 31810868
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
    Maevskaya MV; Kotovskaya YV; Ivashkin VT; Tkacheva ON; Troshina EA; Shestakova MV; Breder VV; Geyvandova NI; Doshchitsin VL; Dudinskaya EN; Ershova EV; Kodzoeva KB; Komshilova KA; Korochanskaya NV; Mayorov AY; Mishina EE; Nadinskaya MY; Nikitin IG; Pogosova NV; Tarzimanova AI; Shamkhalova MS
    Ter Arkh; 2022 Feb; 94(2):216-253. PubMed ID: 36286746
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effects of Robuvit® on the progression of non-alcoholic fatty liver disease.
    Belcaro G; Cox DM; Cesarone MR; Gizzi G; Pellegrini L; Scipione C; Scipione V; Dugall M; Hu S; Corsi M; Feragalli B; Cotellese R
    Minerva Gastroenterol (Torino); 2022 Dec; 68(4):434-441. PubMed ID: 36507829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.